Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clopidogrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Bayer AG
Deal Size : Undisclosed
Deal Type : Acquisition
Corona Remedies Acquires 7 Brands from Bayer's Pharma Division in India
Details : Corona Remedies acquired Bayer’s Noklot (clopidogrel) and six women’s health brands, Fostine, Luprofact, Menodac, Ovidac, Spye, Vageston, to bolster its anti-platelet and hormonal therapy offerings.
Product Name : Noklot
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 17, 2025
Lead Product(s) : Clopidogrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Bayer AG
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Thiocolchicoside
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Recipient : Sanofi
Deal Size : $28.5 million
Deal Type : Acquisition
CORONA Remedies Buys India's Ortho Brand Myoril
Details : Through the acquisition, Corona Remedies gains right for the leading muscle relaxant brand Myoril (thiocolchicoside) and its extensions such as Myoril Plus (ketoprofen and thiocolchicoside) to treat muscular pain.
Product Name : Myoril
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : Thiocolchicoside
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Recipient : Sanofi
Deal Size : $28.5 million
Deal Type : Acquisition
Reset All
